CalciMedica to Host a Call to Review Full Data Set, including a Win Ratio Analysis, from Phase 2b CARPO Trial of AuxoraTM in Acute Pancreatitis (AP)

Conference call and webcast to be held Wednesday, October 30, 2024 at 12 p.m. ET / 9 a.

m. PT LA JOLLA, Calif. , Oct.

28, 2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica") (Nasdaq: CALC ), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that it will host a call on Wednesday, October 30, 2024 at 12 p.m.

ET / 9 a.m. PT to review the full data set and win ratio analysis from the Company's Phase 2b CARPO trial of AuxoraTM in acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS).

Prof. Robert Sutton , University of Liverpool and Liverpool University Hospitals NHS Foundation Trust and chair of the Steering Committee for the CARPO trial, will deliver his plenary presentation from the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting, entitled "A Randomized, Double-Blind, Placebo Controlled Dose Ranging Study of Auxora in Patients with AP and Accompanying SIRS - CARPO." Conference Call and Webcast Details Stockholders and other interested parties may access the call by following the instructions below.

A live webcast of the event can also be accessed in the "Upcoming Events" section of CalciMedica's IR website at https://ir.calcimedica.com/ .

The archived webcast will be available following the completion of the event. Participant Webcast Link: https://ap.